Testosterone on Notably News

Testosterone

Primary male sex hormone

Follow Testosterone on Notably News to receive short updates to your email — rarely!

We include updates on Libido, Metandienone, Pattern hair loss, Late-onset hypogonadism, Digit ratio, Virilization, Voice change, Androgen replacement therapy, Androstanolone, Irritable male syndrome, Male warrior hypothesis, The cream, Free androgen index, James M. Dabbs Jr., Androgen-dependent condition, Silandrone ... and more.

February 2025	Testosterone The US Food and Drug Administration (FDA) specified label changes for testosterone products, removing language about increased cardiovascular risk from the boxed warning and adding a new warning about increased blood pressure. www.fda.gov FDA issues labeling changes for testosterone products following TRAVERSE, postmarket studies www.urologytimes.com
2023	Testosterone Results from the TRAVERSE trial were submitted, concluding no increase in risk of adverse cardiovascular outcomes for men using testosterone for hypogonadism. TRAVERSE Study Supports Cardiovascular Safety of Testosterone Therapy When Used as Indicated consultqd.clevelandclinic.org www.jwatch.org
2023	Pattern hair loss Researchers published a study in the journal PNAS demonstrating that increasing production of a specific microRNA in hair follicle stem cells can soften the cells and stimulate hair growth in genetically engineered mice. The study proposed using nanoparticles for potential future topical human treatment of hair loss. www.pnas.org Baldness breakthrough? New RNA treatment may stimulate hair growth www.medicalnewstoday.com
2022	Testosterone Testosterone became the 118th most commonly prescribed medication in the United States, with over 5 million prescriptions issued.
2020	Testosterone The American College of Physicians issued a guideline supporting discussions about testosterone supplementation for adult men with age-related low testosterone levels experiencing sexual dysfunction. The guideline recommends yearly evaluations and suggests considering intramuscular treatments over transdermal treatments. ACP issues guideline for testosterone treatment in adult men with age-related low testosterone \| ACP Online www.acponline.org
November 2020	Testosterone regulations in women's athletics Semenya announced her intention to file an appeal against the IAAF testosterone rule at the European Court of Human Rights. Caster Semenya loses appeal of CAS ruling on testosterone regulations - Sports Illustrated www.si.com www.washingtonpost.com
September 8 2020	Testosterone regulations in women's athletics The Swiss Federal Supreme Court issued a final ruling denying Semenya's appeal against the testosterone regulations.
July 2020	Testosterone regulations in women's athletics Francine Niyonsaba finished 5th in the 10000m, setting a new National Record for her country.
July 2020	Testosterone regulations in women's athletics Francine Niyonsaba competed in the 5000m but was disqualified for lane infringement while running among the leaders in her heat.
July 2020	Testosterone regulations in women's athletics At the Tokyo Olympics, several African athletes were withdrawn from their original events due to eligibility regulations related to testosterone levels, including Christine Mboma, Beatrice Masilingi, Aminatou Seyni, Caster Semenya, Margaret Wambui, and Francine Niyonsaba.
July 2020	Testosterone regulations in women's athletics Christine Mboma of Namibia won a silver medal in the 200m after being displaced from her original 400m event, becoming an 18-year-old standout athlete in the controversy surrounding testosterone regulations. Tokyo 2020: Coe says Mboma’s 200m silver shows testosterone rules are working – The Irish Times www.irishtimes.com Christine Mboma’s Coach Says Sprinter Will Undergo Hormone Therapy www.runnersworld.com
2019	Testosterone regulations in women's athletics Francine Niyonsaba, the silver medalist from the 2016 Olympics, publicly confirmed having an XY-specific Disorder of Sex Development (DSD) in an interview.
October 2019	Testosterone regulations in women's athletics Semenya, along with silver medalist Francine Niyonsaba and Olympic bronze medalist Margaret Wambui, missed the World Athletics Championships in Doha due to the new regulations.
July 2019	Testosterone regulations in women's athletics Semenya publicly stated that the ongoing legal and regulatory issues have 'destroyed' her 'mentally and physically'.
July 30 2019	Testosterone regulations in women's athletics The Swiss Federal Supreme Court reversed its earlier suspension, allowing the original Court of Arbitration for Sport decision to stand.
June 3 2019	Testosterone regulations in women's athletics Semenya appealed the decision to the Swiss Federal Supreme Court, which initially instructed the IAAF to suspend the eligibility regulations for her specific case.
May 8 2019	Testosterone regulations in women's athletics New IAAF regulations on testosterone in women's athletics came into effect, specifically targeting XY individuals with differences of sex development (DSD).
May 1 2019	Testosterone regulations in women's athletics Caster Semenya lost her case at the Court of Arbitration for Sport, with proceedings revealing she has 5α-reductase deficiency and discussing her unique hormonal biology.
2018	Testosterone A meta-analysis concluded that testosterone treatment is associated with a modest reduction in depressive symptoms in men, with enhanced effectiveness at higher doses and in carefully selected patient populations.
November 1 2018	Testosterone regulations in women's athletics The new IAAF testosterone regulations were set to become effective, with stricter rules targeting athletes with specific Disorders of Sexual Development (DSDs).
October 2018	EC586 Evestra planned to seek Investigational New Drug status for EC586 in the fourth quarter of the year.
June 19 2018	Testosterone regulations in women's athletics Caster Semenya announced her intention to legally challenge the IAAF's testosterone regulations, resulting in the rules being suspended pending legal resolution.
April 23 2018	Testosterone regulations in women's athletics IAAF published new testosterone regulations for women's athletics, covering events from 400m to 1 mile, requiring athletes to reduce testosterone below 5 nmol/L to compete.
August 2016	Testosterone regulations in women's athletics During the Rio 2016 Olympic Games, a controversy erupted over testosterone regulations when South African runner Caster Semenya's participation sparked criticism from competitors Lynsey Sharp and Joanna Jóźwik, who claimed she had a competitive advantage.
2015	Testosterone The FDA stated that neither the benefits nor the safety of testosterone have been established for low testosterone levels due to aging, and required pharmaceutical labels to include warning information about potential increased risks of heart attacks and stroke.
2014	Testosterone A meta-analysis revealed that testosterone improves mood, with notable effects in middle-aged hypogonadal men experiencing subthreshold depression, though showing limited impact in older or eugonadal men.
September 2014	Testosterone FDA initiated a review of the appropriateness and safety of Testosterone Replacement Therapy (TRT) due to potential adverse cardiovascular outcomes.
January 31 2014	Testosterone FDA announced an investigation into reports of strokes, heart attacks, and deaths in men taking FDA-approved testosterone-replacement therapy.
2013	Testosterone A study published in the Journal of the American Medical Association reported that testosterone therapy was significantly associated with increased risk of adverse outcomes.
2011	Testosterone regulations in women's athletics World Athletics (then IAAF) first published testosterone regulations for women athletes, initially applying to all women with high testosterone levels.